Pfizer and Valneva Report Phase 3 Vaccine Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy PFE?
Source: NASDAQ.COM
- Vaccine Efficacy Results: Pfizer and Valneva's Phase 3 trial of the 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 demonstrated an efficacy of 73.2% in reducing confirmed Lyme disease cases from 28 days post-dose 4, indicating significant clinical relevance in preventing Lyme disease.
- Statistical Criteria Not Met: Although the second pre-specified analysis showed an efficacy of 74.8%, the study accrued fewer Lyme disease cases than anticipated, resulting in the first analysis failing to meet the predetermined statistical criteria, which may impact the vaccine's market prospects.
- Regulatory Submission Plans: Pfizer is planning to submit applications to regulatory authorities based on the results of the second analysis, despite the first analysis not meeting the criteria, as the lower bound of the 95% confidence interval exceeded 20, indicating the vaccine's potential value.
- Collaboration Agreement Context: Pfizer and Valneva entered into a collaboration and license agreement in April 2020 for the co-development of PF-07307405, with Pfizer responsible for its manufacturing and commercialization, establishing a strategic partnership that lays the groundwork for the vaccine's future development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 27.280
Low
24.00
Averages
28.56
High
35.00
Current: 27.280
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's GLP-1 Drug Sales Surge Impressively
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound drugs saw sales increase by 99% and 175% respectively in 2025, contributing to an overall sales growth of 45%, highlighting its dominant position in the GLP-1 drug market.
- High Market Valuation: Despite the impressive performance of its GLP-1 drugs, Eli Lilly's price-to-earnings ratio stands at approximately 40x, significantly higher than the S&P 500's 28x and the average pharma stock's 9x, indicating that investors have fully priced in its success.
- Future Competitive Pressure: With patent protections expiring, Eli Lilly faces competition from companies like Novo Nordisk and Pfizer, which are also developing their own GLP-1 drugs, potentially leading to a dramatic decline in revenue from Eli Lilly's products.
- Investment in New Drug Development: Eli Lilly is leveraging the sales revenue from its GLP-1 drugs to invest in new drug development, although the ability to develop new drugs in a complex and highly regulated industry remains a significant challenge.
See More
Eli Lilly's GLP-1 Drug Sales Surge Significantly
- Sales Growth Highlights: Eli Lilly's GLP-1 drugs Mounjaro and Zepbound saw sales increase by 99% and 175% respectively in 2025, contributing nearly 45% of the company's overall sales growth, showcasing their strong market performance.
- Market Leadership Position: Together, Mounjaro and Zepbound accounted for 56% of Eli Lilly's total revenue last year, solidifying its industry-leading position in the GLP-1 drug sector, despite facing competition from Novo Nordisk and Pfizer.
- Valuation Risk: With a price-to-earnings ratio of approximately 40x, significantly higher than the S&P 500's 28x and the average pharma stock's 9x, it suggests that investors may have fully priced in the success of its GLP-1 drugs, posing a risk of rapid stock price decline if market leadership is lost.
- Future Investment Strategy: Despite its current strong performance, Eli Lilly is leveraging the sales revenue from GLP-1 drugs to invest in new drug development and acquisitions; however, the ability to timely launch new drugs in a complex and highly regulated pharmaceutical industry remains a significant challenge.
See More
Merck's Acquisition Sparks Interest in Blood Cancer Drug Market
- Acquisition Premium Analysis: Merck's acquisition of Terns at $53 per share represents a 42% premium, which not only strengthens its blood cancer pipeline but also raises market interest in Sellas, potentially driving up its valuation.
- Investor Sentiment Shift: Following the Merck deal, retail investors are increasingly viewing Pfizer as a potential acquirer of Sellas, reflecting a growing interest in blood cancer drugs and potential M&A opportunities in the sector.
- Clinical Trial Progress: Sellas' Phase 3 Regal trial has recorded 72 death events in AML patients, nearing the 80 required for final analysis, showcasing the clinical potential of its product and likely attracting more investor attention.
- Market Valuation Expectations: Retail investors estimate that Sellas' lead AML candidate, Galinpepimut-S, could be valued between $33.5 billion and $53.6 billion based on projected revenues, indicating optimistic market expectations for its future earnings and further driving demand for its stock.
See More
SLS Shares Surge Following Merck's Tern Acquisition, Fueling Buyout Speculation in Blood Cancer Sector: Retail Investors Eye Major Pharma Contender
Merck's Acquisition of Terns Pharmaceuticals: Merck is set to acquire Terns Pharmaceuticals for $6.7 billion, which includes a 42% premium for the mid-stage leukemia drug TERN-701, enhancing Merck's blood cancer pipeline.
Investor Sentiment Towards Pfizer: Retail investors are increasingly viewing Pfizer as a potential buyer following Merck's acquisition, with attention on Pfizer's ongoing clinical work in hematologic cancers and its need for growth drivers post-COVID.
Sellas Life Sciences Stock Surge: Shares of Sellas Life Sciences jumped over 6% after the announcement of Merck's acquisition, reflecting renewed interest in potential takeovers in the blood cancer drug market.
Focus on Clinical Trials: Investor focus remains on the Phase 3 trial of GPS in AML patients, with significant patient death events recorded, as the study aims to reach final analysis after 80 events, indicating the high stakes involved in these clinical evaluations.
See More
22 S&P 500 Stocks Offering Over 5% Yield: 6 Recommended for Purchase.
Limited High-Yield Stocks: Only 22 non-real-estate stocks in the S&P 500 have dividend yields above 5%, indicating a scarcity of high-yield investment options.
Investment Potential: Despite the limited number, these stocks may still offer attractive income opportunities along with potential for stock appreciation, making them appealing for certain investors.
See More
Pfizer's Clinical Trial Results Spark Market Interest
- Clinical Trial Progress: On March 17, Pfizer announced that its investigational drug atirmociclib performed well in a phase 2 study for second-line metastatic breast cancer, significantly improving progression-free survival when combined with Faslodex, indicating potential in the oncology market.
- Positive Market Reaction: Following the announcement, Pfizer's shares rose approximately 3%, reflecting increased market confidence in its development pipeline, although the company must still succeed in phase 3 trials to advance the drug to market.
- Pipeline Development Strategy: Pfizer plans to initiate around 20 pivotal clinical trials in 2025, particularly in oncology and weight management, suggesting that more significant clinical wins could occur in the coming years, potentially boosting stock prices and financial performance.
- Valuation Appeal: With a current stock price of $27.29 and a price-to-earnings ratio of 9.2, below the healthcare sector average of 16.9, Pfizer presents an attractive investment opportunity given its robust pipeline and reasonable valuation.
See More
Eli Lilly's GLP-1 Drug Sales Surge Impressively
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound drugs saw sales increase by 99% and 175% respectively in 2025, contributing to an overall sales growth of 45%, highlighting its dominant position in the GLP-1 drug market.
- High Market Valuation: Despite the impressive performance of its GLP-1 drugs, Eli Lilly's price-to-earnings ratio stands at approximately 40x, significantly higher than the S&P 500's 28x and the average pharma stock's 9x, indicating that investors have fully priced in its success.
- Future Competitive Pressure: With patent protections expiring, Eli Lilly faces competition from companies like Novo Nordisk and Pfizer, which are also developing their own GLP-1 drugs, potentially leading to a dramatic decline in revenue from Eli Lilly's products.
- Investment in New Drug Development: Eli Lilly is leveraging the sales revenue from its GLP-1 drugs to invest in new drug development, although the ability to develop new drugs in a complex and highly regulated industry remains a significant challenge.
See More
Eli Lilly's GLP-1 Drug Sales Surge Significantly
- Sales Growth Highlights: Eli Lilly's GLP-1 drugs Mounjaro and Zepbound saw sales increase by 99% and 175% respectively in 2025, contributing nearly 45% of the company's overall sales growth, showcasing their strong market performance.
- Market Leadership Position: Together, Mounjaro and Zepbound accounted for 56% of Eli Lilly's total revenue last year, solidifying its industry-leading position in the GLP-1 drug sector, despite facing competition from Novo Nordisk and Pfizer.
- Valuation Risk: With a price-to-earnings ratio of approximately 40x, significantly higher than the S&P 500's 28x and the average pharma stock's 9x, it suggests that investors may have fully priced in the success of its GLP-1 drugs, posing a risk of rapid stock price decline if market leadership is lost.
- Future Investment Strategy: Despite its current strong performance, Eli Lilly is leveraging the sales revenue from GLP-1 drugs to invest in new drug development and acquisitions; however, the ability to timely launch new drugs in a complex and highly regulated pharmaceutical industry remains a significant challenge.
See More
Merck's Acquisition Sparks Interest in Blood Cancer Drug Market
- Acquisition Premium Analysis: Merck's acquisition of Terns at $53 per share represents a 42% premium, which not only strengthens its blood cancer pipeline but also raises market interest in Sellas, potentially driving up its valuation.
- Investor Sentiment Shift: Following the Merck deal, retail investors are increasingly viewing Pfizer as a potential acquirer of Sellas, reflecting a growing interest in blood cancer drugs and potential M&A opportunities in the sector.
- Clinical Trial Progress: Sellas' Phase 3 Regal trial has recorded 72 death events in AML patients, nearing the 80 required for final analysis, showcasing the clinical potential of its product and likely attracting more investor attention.
- Market Valuation Expectations: Retail investors estimate that Sellas' lead AML candidate, Galinpepimut-S, could be valued between $33.5 billion and $53.6 billion based on projected revenues, indicating optimistic market expectations for its future earnings and further driving demand for its stock.
See More
SLS Shares Surge Following Merck's Tern Acquisition, Fueling Buyout Speculation in Blood Cancer Sector: Retail Investors Eye Major Pharma Contender
Merck's Acquisition of Terns Pharmaceuticals: Merck is set to acquire Terns Pharmaceuticals for $6.7 billion, which includes a 42% premium for the mid-stage leukemia drug TERN-701, enhancing Merck's blood cancer pipeline.
Investor Sentiment Towards Pfizer: Retail investors are increasingly viewing Pfizer as a potential buyer following Merck's acquisition, with attention on Pfizer's ongoing clinical work in hematologic cancers and its need for growth drivers post-COVID.
Sellas Life Sciences Stock Surge: Shares of Sellas Life Sciences jumped over 6% after the announcement of Merck's acquisition, reflecting renewed interest in potential takeovers in the blood cancer drug market.
Focus on Clinical Trials: Investor focus remains on the Phase 3 trial of GPS in AML patients, with significant patient death events recorded, as the study aims to reach final analysis after 80 events, indicating the high stakes involved in these clinical evaluations.
See More
22 S&P 500 Stocks Offering Over 5% Yield: 6 Recommended for Purchase.
Limited High-Yield Stocks: Only 22 non-real-estate stocks in the S&P 500 have dividend yields above 5%, indicating a scarcity of high-yield investment options.
Investment Potential: Despite the limited number, these stocks may still offer attractive income opportunities along with potential for stock appreciation, making them appealing for certain investors.
See More
Pfizer's Clinical Trial Results Spark Market Interest
- Clinical Trial Progress: On March 17, Pfizer announced that its investigational drug atirmociclib performed well in a phase 2 study for second-line metastatic breast cancer, significantly improving progression-free survival when combined with Faslodex, indicating potential in the oncology market.
- Positive Market Reaction: Following the announcement, Pfizer's shares rose approximately 3%, reflecting increased market confidence in its development pipeline, although the company must still succeed in phase 3 trials to advance the drug to market.
- Pipeline Development Strategy: Pfizer plans to initiate around 20 pivotal clinical trials in 2025, particularly in oncology and weight management, suggesting that more significant clinical wins could occur in the coming years, potentially boosting stock prices and financial performance.
- Valuation Appeal: With a current stock price of $27.29 and a price-to-earnings ratio of 9.2, below the healthcare sector average of 16.9, Pfizer presents an attractive investment opportunity given its robust pipeline and reasonable valuation.
See More
